Troglitazone

CHF 75.00
In stock
AG-CR1-3565-M0055 mgCHF 75.00
AG-CR1-3565-M02525 mgCHF 320.00
More Information
Product Details
Synonyms 5-[[4-[(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione; Romglizone; BRN 4338399; CS-045; CI-991; GR 92132X
Product Type Chemical
Properties
Formula

C24H27NO5S

MW 441.5
Merck Index 14: 9769
CAS 97322-87-7
RTECS XJ5813130
Purity Chemicals ≥98%
Appearance White to off-white solid.
Solubility Soluble in DMSO, ethanol or dimethylformamide (DMF).
InChi Key GXPHKUHSUJUWKP-UHFFFAOYSA-N
Smiles CC1=C(C)C2=C(CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)O2)C(C)=C1O
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Protect from light.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Potent and selective PPARγ agonist with no activation of PPARα and PPARδ [2].
  • Anti-diabetic agent with potent glucose-lowering effects and decreasing insulin resistance in adipose tissues. Stimulates adipogenesis [1, 6, 8].
  • Apoptosis and cell cycle arrest inducer in several cancer cell lines [3-8].
  • Anti-inflammatory [8-10, 12].
  • Inhibits vascular smooth muscle cell (VSMC) migration [11].
Product References
  1. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats: T. Fujiwara, et al.; Diabetes 37, 1549 (1988)
  2. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma): J.M. Lehmann, et al.; J. Biol. Chem. 270, 12953 (1995)
  3. Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids: H. Asou, et al.; Int. J. Oncol. 15, 1027 (1999)
  4. Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators: Y. Kodera, et al.; J. Biol. Chem. 275, 33201 (2000)
  5. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis: Y. Tsubouchi, et al.; BBRC 270, 400 (2000)
  6. Troglitazone and related compounds: therapeutic potential beyond diabetes: T. Fujiwara & H. Horikoshi; Life Sci. 67, 2405 (2000)
  7. Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells: T. Okura, et al.; Eur. J. Pharmacol. 407, 227 (2000)
  8. Troglitazone and related compounds: therapeutic potential beyond diabetes: T. Fujiwara & H. Horikoshi; Life Sci. 67, 2405 (2000) (Review)
  9. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese: H. Ghanim, et al.; J. Clin. Endocrinol. Metab. 86, 1306 (2001)
  10. Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: A. Aljada, et al.; evidence of an antiinflammatory action?: J. Clin. Endocrinol. Metab. 86, 3250 (2001)
  11. Peroxisome proliferator-activated receptor-gamma ligands inhibit nuclear but not cytosolic extracellular signal-regulated kinase/mitogen-activated protein kinase-regulated steps in vascular smooth muscle cell migration: S. Goetze, et al.; J. Cardiovasc. Pharmacol. 38, 909 (2001)
  12. Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300: K. Subbaramaiah, et al.; J. Biol. Chem. 276, 12440 (2001)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.